John Hayslip, MD, executive medical director at AbbVie Pharmaceuticals discusses new data testing venetoclax and azacitidine in patients with acute myeloid leukemia (AML).
AML is a blood cancer that most often occurs in people over the age of 40 years. Signs and symptoms can vary but for many patients, the cancer can be very aggressive and may require intensive treatment. AML patients with comorbidities or who are elderly may not be eligible for intensive therapy in which case effective, more tolerable treatments are needed.
At ASH 2020, pooled data from an ongoing Phase 3 and 1b studies testing venetoclax and azacitidine in AML patients ineligible for intensive treatment was presented.
As Dr. Hayslip explains, the combination of venetoclax and azacitidine had significantly better response rates compared to azacitidine alone.
For the latest developments from ASH 2020 and other medical conferences, be sure to sign up for our newsletter at checkrare.com/sign-up/